Annals of internal medicine
-
Randomized Controlled Trial Multicenter Study
Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
Observational studies from Asia suggest that maxingshigan-yinqiaosan may be effective in the treatment of acute H1N1 influenza. ⋯ Beijing Science and Technology Project and Beijing Nova Program.
-
Multicenter Study Comparative Study
Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study.
Several clinical decision rules (CDRs) are available to exclude acute pulmonary embolism (PE), but they have not been directly compared. ⋯ Academic Medical Center, VU University Medical Center, Rijnstate Hospital, Leiden University Medical Center, Maastricht University Medical Center, Erasmus Medical Center, and Maasstad Hospital.
-
Randomized Controlled Trial Multicenter Study
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Inhaled corticosteroids (ICS) and long-acting β(2)-agonists (LABAs) are recommended in patients with asthma that is not well-controlled; however, many patients continue to have inadequately controlled asthma despite this therapy. ⋯ Genentech and Novartis Pharmaceuticals.
-
Multicenter Study
Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study.
Each year, millions of patients worldwide have a perioperative myocardial infarction (MI) after noncardiac surgery. ⋯ Most patients with a perioperative MI will not experience ischemic symptoms. Data suggest that routine monitoring of troponin levels in at-risk patients is needed after surgery to detect most MIs, which have an equally poor prognosis regardless of whether they are symptomatic or asymptomatic.
-
Randomized Controlled Trial Multicenter Study
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Limited data compare once-daily options for initial therapy for HIV-1. ⋯ National Institutes of Health.